Figure 7: Guanabenz treatment alleviates clinical severity of relapse in mice with relapsing-remitting EAE. | Nature Communications

Figure 7: Guanabenz treatment alleviates clinical severity of relapse in mice with relapsing-remitting EAE.

From: Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic

Figure 7

Six- to eight-week old female SJL mice were immunized with proteolipid protein 139–151 to induce R-EAE. R-EAE mice that displayed an acute phase of disease were treated at the beginning of remission (on average 5 days after onset of disease) with vehicle (n=13) or 8 mg kg−1 of guanabenz (n=14) daily and monitored for clinical symptoms. All R-EAE mice that displayed no relapse (9 out of 22 vehicle-treated and 9 out of 23 guanabenz-treated) were removed from the analysis. Unpaired t-test, *P<0.05. Data are presented as mean±s.e.m. Clinical scores of each treatment group are aligned by day of onset of disease (defined as the day the mouse reaches a clinical score of 1) and averaged by day. One representative experiment of two is presented.

Back to article page